It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age. We demonstrate strong links between mitochondrial and nuclear mutational profiles, with co-occurrence between specific mutations. For example, certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival. These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada
2 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; Biotech Research & Innovation Centre (BRIC) and Finsen Laboratory, Copenhagen, Denmark
3 Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5 Biotech Research & Innovation Centre (BRIC) and Finsen Laboratory, Copenhagen, Denmark
6 Division of Theoretical Bioinformatics, German Cancer Research Center, Heidelberg, Germany
7 Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany
8 Genome Technologies Program, Ontario Institute for Cancer Research, Toronto, ON, Canada
9 Department of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, ON, Canada
10 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
11 Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada
13 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada